The problem of polypharmacy in type 2 diabetes

Alistar Emslie-Smith*, Jon Dowall, Andrew Morris

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Evidence of improvements in outcomes gained by aggressive treatment of hypertension, hyperglycaemia and dyslipidaemia in type 2 diabetic patients has encouraged the setting of ambitious targets for risk factor control. The therapeutic regimens needed to achieve tight control results in polypharmacy for many patients. The recent DARTS Study demonstrated poor adherence to oral hypoglycaemic drug therapy, particularly in patients prescribed combination oral hypoglycaemic drug therapy, multiple daily dose regimens and co-medications. This suggests that simplifying drug regimens, minimising tablet-counts and the use of once-daily and modified-release preparations and of fixed-combination drug preparations may be important. With regard to taking medication an alliance is needed which allows greater mutual understanding and agreement between patient and doctor. This move towards 'concordance' in care planning is also crucial to success.

Original languageEnglish
Pages (from-to)54-56
Number of pages3
JournalBritish Journal of Diabetes and Vascular Disease
Volume3
Issue number1
Publication statusPublished - 1 Jan 2003

Keywords / Materials (for Non-textual outputs)

  • Adherence
  • Concordance
  • Polypharmacy
  • Therapeutic alliance

Fingerprint

Dive into the research topics of 'The problem of polypharmacy in type 2 diabetes'. Together they form a unique fingerprint.

Cite this